Group 1 - The core viewpoint of the article highlights the financial performance of Zhongyao Holdings in Q3 2023, showing growth in revenue and net profit compared to the previous year [1] Group 2 - For the first three quarters of 2025, the company reported revenue of approximately 62.211 billion yuan, an increase of 4.22% year-on-year [1] - The net profit attributable to shareholders was approximately 384 million yuan, reflecting a year-on-year increase of 31.41% [1] - The basic earnings per share were 0.22 yuan, which is a 29.41% increase compared to the same period last year [1] Group 3 - As of the report date, the market capitalization of Zhongyao Holdings is 9.2 billion yuan [2]

Core Viewpoint - The company reported a revenue of 21.023 billion yuan for Q3 2025, marking a year-on-year growth of 5.57% and a net profit attributable to shareholders of 102 million yuan, which represents a significant increase of 87.94% [1] Financial Performance - For the first three quarters of 2025, the company achieved a total revenue of 62.211 billion yuan, reflecting a year-on-year growth of 4.22% [1] - The net profit attributable to shareholders for the same period was 384 million yuan, showing a year-on-year increase of 31.41% [1] - The basic earnings per share for Q3 2025 was reported at 0.06 yuan [1]

Core Points - Dacilin announced on October 27 that it received a notification from its controlling shareholder, Mr. Ke Jinlong, regarding the release of a portion of his pledged shares, totaling 31,680,000 shares [1] Summary by Category Company Actions - Dacilin has completed the registration procedures for the release of the pledged shares [1] Shareholder Information - Mr. Ke Jinlong, a controlling shareholder, is the individual who notified the company about the release of the pledged shares [1]

Group 1 - The core viewpoint of the article highlights the financial performance of Jianfa Zhixin for the third quarter of 2023, showing significant growth in revenue and net profit [1] - For the first three quarters of 2025, the company reported revenue of approximately 14.861 billion yuan, an increase of 10.18% year-on-year [1] - The net profit attributable to shareholders was about 230 million yuan, reflecting a year-on-year increase of 45.01% [1] - The basic earnings per share reached 0.64 yuan, which is a 45.45% increase compared to the previous year [1] Group 2 - As of the report date, Jianfa Zhixin's market capitalization stands at 16.6 billion yuan [2]

Core Viewpoint - China Medical (600056.SH) reported a decline in revenue and net profit for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The total operating revenue for the first three quarters reached 25.894 billion yuan, representing a year-on-year decrease of 3.42% [1] - The net profit attributable to shareholders was 455 million yuan, down 4.64% year-on-year [1] - The basic earnings per share stood at 0.304 yuan [1]

Group 1 - The core point of the article is that Jiuzhoutong (600998.SH) reported its third-quarter results, showing a total operating revenue of 119.327 billion yuan for the first three quarters of 2025, which represents a year-on-year increase of 5.2% [1] - The net profit attributable to the shareholders of the parent company reached 1.975 billion yuan, reflecting a year-on-year growth of 16.46% [1] - The basic earnings per share (EPS) for the company is reported at 0.39 yuan [1]

Group 1 - The core point of the article is that China National Pharmaceutical Group (SH 600056) held its 32nd board meeting on October 27, 2025, to review the proposal for amending the "Major Information Internal Reporting System" [1] - For the first half of 2025, the revenue composition of China National Pharmaceutical Group is as follows: pharmaceutical commerce accounts for 75.5%, pharmaceutical trade 13.26%, chemical preparations 3.97%, health and e-commerce 3.54%, and raw materials 2.82% [1] - As of the time of reporting, the market capitalization of China National Pharmaceutical Group is 16.6 billion yuan [1]

九州通公告，第三季度营收为382.2亿元，同比增长5.41%；净利润为5.3亿元，同比增长8.46%。前三季 度营收为1193.27亿元，同比增长5.20%；净利润为19.75亿元，同比增长16.46%。 ...

达嘉维康公告，第三季度营收为14.22亿元，同比增长2.79%；净利润为420.38万元，下降8.94%。前三 季度营收为41.3亿元，同比增长3.69%；净利润为509.74万元，下降86.02%。 ...

國藥控股股份有限公司截至 2025 年 9 月 30 日止九個月之未經審核財務報表 ( 於中華人民共和國註冊成立之股份有限公司 , 在香港以國控股份有限公司之名稱經營業務 ) (股份代號 :01099) 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條作出。 茲載列國藥控股股份有限公司（「本公司」）於 2025 年 10 月 27 日於上海證券交易所網 站 (http://www.sse.com.cn)、中國貨幣網網站(http://www.chinamoney.com.cn)及上海清算所 網站(http://www.shclearing.com)發佈的截至 2025 年 9 月 30 日止九個月之合併以及本公司 的未經審核資產負債表、利潤表、現金流量表及所有者權益變動表，僅供參閱。 承董事會命 國藥控股股份有限公司 董事長 趙炳祥 中國，上海 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚賴該等內 容而引致之任何損失承擔任何責任。 2025年 10月 27日 ...